Revenue
2021
2022
2023
2024
2025
Nika Pharmaceuticals, Inc (NIKA)
Price$0.4100Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | — | — | $0 | $3.0M | $0 | — | — |
| Operating expenses | $76,398 | $95,792 | $64,833 | $3.2M | $14,712 | $8,907 | — |
| Operating income | −$76,398 | −$95,792 | −$64,833 | −$3.2M | −$14,712 | −$8,907 | — |
| EBITDA | −$76,398 | −$95,792 | −$64,833 | −$3.2M | — | — | — |
| Net income | −$76,398 | −$95,792 | −$64,833 | −$3.2M | −$14,712 | −$8,907 | — |
| Basic EPSper basic share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Diluted EPSper diluted share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Savov Dimitar Slavchev | 455.59M |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 18, 2025Form 4 | Savov Dimitar SlavchevCEO, CFO, President | SellCommon Stock | 2.00M | $0.25 | $500.0K | 455.59M |